Key result
SynCardia temporary total artificial heart achieves 71% overall survival in pediatric end-stage heart failure.
Why the study?
The development of the smaller 50 cc TAH-t expanded potential pediatric applications, prompting an evaluation of evolving device use and clinical outcomes over time.
Observational (n=51)
Yes
The SynCardia temporary total artificial heart is an effective biventricular support strategy for pediatric patients with end-stage heart failure, achieving a 71% overall survival to transplant or ongoing support.
BACKGROUND: The use of the SynCardia temporary total artificial heart (TAH-t) in adults has increased with time. The development of the smaller, 50 cc TAH-t has expanded the potential applications of the device in children. We sought to describe the evolving use of the TAH-t over time and describe outcomes in the current era. METHODS: The SynCardia database was queried to identify all pediatric patients ≤18 years of age implanted with the device between December 1985 and October 2019. Patient demographics, clinical outcome and support characteristics collected. RESULTS: Fifty-one children were supported, 36 with the 70 cc TAH-t and 15 with the 50 cc TAH-t with a total support time of 6,243 days. The number of implants has increased with time (19 between 2015 and 2019). A total of 13 patients have been converted to Freedom Driver support, seven 50 cc TAH-t and six 70 cc TAH-t. The majority of implants in the last 5 years (15/19, 79%) have been with the 50 cc TAH-t. The most common diagnosis was dilated cardiomyopathy [24 (47%)] and the average age at the time of implant was 16±2 years old. Overall survival for the patient cohort was 71%. CONCLUSIONS: The use of the SynCardia TAH-t to support children with end-stage heart failure has increased over time. Clinical outcomes with both the 50 cc and 70 cc TAH-t are similar to reported outcomes in adults who require TAH-t or other methods of biventricular support.
No takes yet. Share an insight, caveat, or question.
Villa et al. (2020) conducted an observational in End-stage heart failure (n=51). SynCardia temporary total artificial heart (TAH-t) was evaluated on Overall survival (alive on device or transplanted). The SynCardia temporary total artificial heart supported pediatric patients with end-stage heart failure, achieving an overall survival (alive on device or transplanted) rate of 71%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: